ResMed Newswire

ResMed Newswire

Comprehensive Real-Time News Feed for ResMed.

Results 1 - 20 of 338 in ResMed

  1. ResMed (RMD) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Yesterday | The Breeze

    According to Zacks, "Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations.

    Comment?

  2. ResMed Inc. (RMD) Receives Consensus Rating of "Hold" from AnalystsRead the original story w/Photo

    Monday | AmericanBankingNews.com

    ResMed Inc. has been given a consensus rating of "Hold" by the thirteen research firms that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company.

    Comment?

  3. Cubist Systematic Strategies LLC Acquires Shares of 1,467 ResMed Inc.Read the original story w/Photo

    Monday | IntersportsWire

    Cubist Systematic Strategies LLC acquired a new stake in ResMed Inc. in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The firm acquired 1,467 shares of the medical equipment provider's stock, valued at approximately $113,000.

    Comment?

  4. Dimensional Fund Advisors LP Purchases 54,563 Shares of ResMed Inc.Read the original story w/Photo

    Monday | IntersportsWire

    Dimensional Fund Advisors LP grew its stake in ResMed Inc. by 14.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 433,880 shares of the medical equipment provider's stock after acquiring an additional 54,563 shares during the quarter.

    Comment?

  5. ResMed (RMD) Set to Announce Quarterly Earnings on MondayRead the original story w/Photo

    Monday | AmericanBankingNews.com

    ResMed will be announcing its earnings results after the market closes on Monday, January 22nd. Analysts expect the company to announce earnings of $0.78 per share for the quarter.

    Comment?

  6. $577.00 Million in Sales Expected for ResMed Inc. (RMD) This QuarterRead the original story w/Photo

    Saturday Jan 13 | AmericanBankingNews.com

    Equities research analysts predict that ResMed Inc. will report sales of $577.00 million for the current quarter, Zacks reports. Two analysts have made estimates for ResMed's earnings, with the lowest sales estimate coming in at $571.00 million and the highest estimate coming in at $583.00 million.

    Comment?

  7. ResMed Inc. (RMD) Expected to Post Earnings of $0.78 Per ShareRead the original story w/Photo

    Thursday Jan 11 | AmericanBankingNews.com

    Wall Street brokerages predict that ResMed Inc. will post earnings per share of $0.78 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ResMed's earnings, with estimates ranging from $0.75 to $0.81.

    Comment?

  8. ResMed (RMD) Downgraded to "Hold" at Zacks Investment ResearchRead the original story w/Photo

    Thursday Jan 11 | AmericanBankingNews.com

    According to Zacks, "Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations.

    Comment?

  9. Diagnosing, Treating Sleep Apnea in Hospital Improves Survival, Says...Read the original story

    Tuesday Jan 9 | Newkerala.com

    SAN DIEGO: Undiagnosed sleep apnea is highly prevalent among hospital patients, and treating it after they're discharged can improve their chances of long-term survival, according to a ResMed-funded study published in the American Journal of Medicine. The study screened more than 5,000 hospitalized patients; 18.7 percent were estimated to have sleep apnea.

    Comment?

  10. ResMed (RMD) Upgraded to Hold by Zacks Investment ResearchRead the original story w/Photo

    Saturday Jan 6 | Daily Political

    According to Zacks, "Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations.

    Comment?

  11. Zacks Investment Research Upgrades ResMed (RMD) to HoldRead the original story w/Photo

    Friday Jan 5 | AmericanBankingNews.com

    According to Zacks, "Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations.

    Comment?

  12. ResMed Inc. (RMD) CFO Brett Sandercock Sells 1,250 Shares of StockRead the original story w/Photo

    Friday Jan 5 | IntersportsWire

    ResMed Inc. CFO Brett Sandercock sold 1,250 shares of the company's stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $84.99, for a total value of $106,237.50.

    Comment?

  13. Financial Survey: ResMedRead the original story w/Photo

    Thursday Jan 4 | AmericanBankingNews.com

    ResMed and Waters are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation. ResMed pays an annual dividend of $1.40 per share and has a dividend yield of 1.6%.

    Comment?

  14. ResMed (RMD) Receiving Somewhat Positive Media Coverage, Analysis FindsRead the original story w/Photo

    Thursday Jan 4 | Daily Political

    Media headlines about ResMed have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time.

    Comment?

  15. ResMed Inc. (RMD)'s Chief Financial Officer Brett Sandercock Sold...Read the original story w/Photo

    Thursday Jan 4 | Hill Country Times

    ResMed Inc. 's Chief Financial Officer Brett Sandercock Sold 1250 shares of the Company; Profile of 0 Analysts Covering The Andersons, Inc. Brett Sandercock, an insider and also Chief Financial Officer of the popular company Resmed Inc made transaction. He made a sale of 1,250 shares of the firm with the deal having a market value of $106,238 U.S Dollars - estimated based on $85.0 per share.

    Comment?

  16. ResMed Inc. (RMD) CFO Sells $106,237.50 in StockRead the original story w/Photo

    Thursday Jan 4 | Daily Political

    ResMed Inc. CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $84.99, for a total value of $106,237.50.

    Comment?

  17. James Hollingshead Sells 600 Shares of ResMed Inc. (RMD) StockRead the original story w/Photo

    Thursday Jan 4 | AmericanBankingNews.com

    ResMed Inc. insider James Hollingshead sold 600 shares of the business's stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $84.96, for a total value of $50,976.00.

    Comment?

  18. Resmed (RMD) Shareholder Commonwealth Of Pennsylvania Public School...Read the original story

    Wednesday Jan 3 | Hill Country Times

    Resmed Shareholder Commonwealth Of Pennsylvania Public School Empls Retrmt Sys Cut Its Position by $694,108; As Howard Hughes Share Value Rose, Locust Wood Capital Advisers Boosted Its Stake Stephen J. Errico increased its stake in Howard Hughes Corp by 32.71% based on its latest 2017Q3 regulatory filing with the SEC. Locust Wood Capital Advisers Llc bought 86,629 shares as the company's stock rose 10.78% with the market.

    Comment?

  19. Zacks: Brokerages Anticipate ResMed Inc. (RMD) Will Post Quarterly Sales of $577.00 MillionRead the original story w/Photo

    Thursday Dec 28 | AmericanBankingNews.com

    Brokerages expect that ResMed Inc. will announce $577.00 million in sales for the current fiscal quarter, according to Zacks . Two analysts have provided estimates for ResMed's earnings.

    Comment?

  20. ResMed (RMD) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Thursday Dec 28 | IntersportsWire

    According to Zacks, "Challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to foreign exchange fluctuations.

    Comment?